I worry this comment is overly dismissive of criticisms and overly optimistic about potential positives. On medicine topics I think it is important to try remain objective.
1. On DXM being an NMDA antagonist:
At high concentration DXM is an NMDA antagonist and AXS-05 does dramatically increases DXM concentration [0] (slide 6). It is not clear to me why we should "ignore anyone" who makes this comparison?
2. On AXS-05 having a wide array of receptor targets:
Almost all psychoactive drugs have some affinity for many receptors (just wikipedia any anti-psychotic e.g. [1]). Are any of the targets mentioned clinically significant at therapeutic concentrations?
1. On DXM being an NMDA antagonist: At high concentration DXM is an NMDA antagonist and AXS-05 does dramatically increases DXM concentration [0] (slide 6). It is not clear to me why we should "ignore anyone" who makes this comparison?
2. On AXS-05 having a wide array of receptor targets: Almost all psychoactive drugs have some affinity for many receptors (just wikipedia any anti-psychotic e.g. [1]). Are any of the targets mentioned clinically significant at therapeutic concentrations?
[0] https://axsometherapeuticsinc.gcs-web.com/static-files/4a508... [1] https://en.wikipedia.org/wiki/Olanzapine